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1. PUBLIC HEALTH STATEMENT 
This Statement was prepared to give you information about pyridine and to emphasize the human 
health effects that may result from exposure to it. The Environmental Protection Agency (EPA) has 
identified 1,177 sites on its National Priorities List (NPL). Pyridine has been found at 4 of these sites. 
However, we do not know how many of the 1,177 NPL sites have been evaluated for pyridine. As EPA 
evaluates more sites, the number of sites at which pyridine is found may change. This information is 
important for you to know because pyridine may cause harmful health effects and because these sites 
are potential or actual sources of human exposure to pyridine. 
When a chemical is released from a large area, such as an industrial plant, or from a container, such 
as a drum or bottle, it enters the environment as a chemical emission. This emission, which is also 
called a release, does not always lead to exposure. You can be exposed to a chemical only when you 
come into contact with the chemical. You may be exposed to it in the environment by breathing, 
eating, or drinking substances containing the chemical or from skin contact with it. 
If you are exposed to a hazardous chemical such as pyridine, several factors will determine whether 
harmful health effects will occur and what the type and severity of those health effects will be. These 
factors include the dose (how much), the duration (how long), the route or pathway by which you are 
exposed (breathing, eating, drinking, or skin contact), the other chemicals to which you are exposed, 
and your individual characteristics such as age, sex, nutritional status, family traits, life style, and state 
of health. 
1.1 WHAT IS PYRIDINE? 
Pyridine is a flammable colorless liquid with an unpleasant smell. It can be made from crude coal 
tar or from other chemicals. Pyridine is used as a solvent and to make many different products such as 
medicines, vitamins, food flavorings, pesticides, paints, dyes, rubber products, adhesives, and 
waterproofing for fabrics. Pyridine can also be formed from the breakdown of many natural materials 
in the environment. Many of the foods that you eat have flavors that are the result of complex 
compounds that contain pyridine.  
Liquid pyridine evaporates into the air very easily. If pyridine is released to the air, it may take 
several months to years until it breaks down into other compounds. Pyridine also mixes very easily 
with water. If it is released to water or soil, it may break down in a few days to few months.  
You may find information on the properties and uses of pyridine and how it behaves in the 
environment in Chapters 3, 4, and 5. 
1.2 HOW MIGHT I BE EXPOSED TO PYRIDINE? 
Pyridine and pyridine-containing compounds are present throughout the environment at very low 























1. PUBLIC HEALTH STATEMENT 
around factories that produce it or use it to make other products. You could be exposed to pyridine if 
you work in one of these factories or if you live or work near a hazardous waste site that releases it to 
the surrounding air. Pyridine is also released into the air from burning cigarettes and from hot coffee. 
Pyridine is not usually found in rivers or other natural waters. It has been found in wells in an 
industrial area in Wyoming. The levels of pyridine in the well water were as high as 53 parts of 
pyridine in 1 billion parts of water (53 ppb). Pyridine is not usually found in the soil near hazardous 
waste sites or in industrial areas. Pyridine has been found in drinking water samples taken around 
hazardous waste sites and industrial areas. However, we do not know the levels. It is also found in 
certain foods such as fried chicken, cheese, and fried bacon. Although the levels in these foods are not 
known, they are probably very low and are not expected to result in any health effects. The level of 
pyridine in some frozen mango (a tropical fruit) was reported to be 1 part of pyridine per million parts 
of mango (1 ppm). You could be exposed to small amounts of pyridine if you eat these foods or drink 
water containing pyridine. 
You can find more information on how you might be exposed to pyridine in Chapter 5. 
1.3 HOW CAN PYRIDINE ENTER AND LEAVE MY BODY? 
Pyridine can enter your body when you breathe in air, drink water, or eat food that contains this 
chemical, or by skin contact with the chemical. When it enters your body by mouth, more than half of 
it is absorbed. Within 1 day, most of what was absorbed leaves your body in urine as pyridine itself or 
its breakdown products. We do not know what happens to the rest of it. There is also no information 
about what happens to pyridine that is breathed in or gets on your skin. 
You can find more information on how pyridine enters and leaves the body in Chapter 2. 
1.4 HOW CAN PYRIDINE AFFECT MY HEALTH? 
Very few studies have been conducted to determine the possible effects of pyridine exposure on 
human health. From case reports on humans and studies in animals, we think the most important health 
concern for humans exposed to pyridine will be damage to the liver. Other health concerns for humans 
may be neurological effects, renal effects, and irritation of the skin and eye. We do not know whether 
pyridine can cause cancer, birth defects, or problems with reproduction. 
You can find more information on health effects of pyridine in humans and animals in Chapter 
2. 
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1.5	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO PYRIDINE? 
Tests can be used to find out whether you have been recently exposed to pyridine. These tests 
measure levels of pyridine in urine and blood. They use special equipment and are done in special 
laboratories, so they are not usually available in a doctor's office. The levels of pyridine in urine or 
blood cannot be used, however, to find out how much pyridine you were exposed to or whether 
specific harmful effects will occur. 
You will find more information on how pyridine can be measured in exposed humans in 
Chapters 2 and 6. 
1.6 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government has set certain regulations and guidelines to help protect people from 
the possible health effects of pyridine in the environment. The EPA has not set limits on the amount of 
pyridine that may be present in drinking water. The Occupational Safety and Health Administration 
(OSHA) has set an average air exposure level of 5 ppm for an g-hour day, 40-hour work week. The 
National Institute for Occupational Safety and Health (NIOSH) has set 3,600 ppm in air as the level 
that is immediately dangerous to life and health (IDLH). The American Conference of Governmental 
Industrial Hygienists (ACGIH), which is a special nongovernment group set up to protect workers, also 
recommends 5 ppm for an g-hour day. 
You will find more information on governmental rules for pyridine in Chapter 7. 
1.7 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns not covered here, please contact your state health 
or environmental department or: 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology 
1600 Clifton Road, E-29 
Atlanta, Georgia 30333 
This agency can also provide you with information on the location of the nearest occupational 
and environmental health clinic. Such clinics specialize in recognizing, evaluating, and treating 










































































2. HEALTH EFFECTS 
2.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, 
toxicologists, and other interested individuals and groups with an overall perspective of the toxicology 
of pyridine and a depiction of significant exposure levels associated with various adverse health 
effects. It contains descriptions and evaluations of studies and presents levels of significant exposure 
for pyridine based on toxicological studies and epidemiological investigations. 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure-­
inhalation, oral, and dermal--and then by health effect--death, systemic, immunological, neurological, 
developmental, reproductive, genotoxic, and carcinogenic effects. These data are discussed in terms of 
three exposure periods--acute (less than 15 days), intermediate (15-364 days), and chronic (365 days or 
more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated 
in figures. The points in the figures showing noobserved-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the 
studies. LOAELs have been classified into "less serious" or "serious" effects, These distinctions are 
intended to help the users of the document identify the levels of exposure at which adverse health 
effects start to appear. They should also help to determine whether or not the effects vary with dose 
and/or duration, and place into perspective the possible 
significance of these effects to human health. 
The significance of the exposure levels shown in the tables and figures may differ depending 
on the user's perspective. For example, physicians concerned with the interpretation of clinical findings 
in exposed persons may be interested in levels of exposure associated with "serious" effects. Public 
health officials and project managers concerned with appropriate actions to take at hazardous waste 
sites may want information on levels of exposure associated with more subtle effects in humans or 
animals (LOAEL) or exposure levels below which no adverse effects (NOAEL) have been observed.  
Estimates of levels posing minimal risk to humans (Minimal Risk Levels, MRLs) may be of 
interest to health professionals and citizens alike. Estimates of exposure levels posing minimal risk to 
humans (MRLs) have been made, where data were believed reliable, for the most sensitive noncancer 
effect for each exposure duration. MRLs include adjustments to reflect human variability from


























2. HEALTH EFFECTS 
Although methods have been established to derive these levels (Barnes et al. 1988; EPA 1989a), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in 
development or are acquired following repeated acute insults, such as hypersensitivity reactions, 
asthma, or chronic bronchitis. As these kinds of health effects data become available and methods to 
assess levels of significant human exposure improve, these MRLs will be revised. 
2.2.1 Inhalation Exposure 
2.2.1.1 Death 
No studies were located regarding death in humans after inhalation exposure to pyridine. 
A l-hour LC50 for pyridine of 9,010 ppm for male rats and of 9,020 ppm for female rats was 
reported by Vernot et al. (1977). 
These l-hour LC50 levels for rats are recorded in Table 2-l and plotted 
in Figure 2-l. 
2.2.1.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, or dermal/ocular effects in humans or animals after inhalation exposure to 
pyridine. 
Renal Effects. No useful studies were located regarding renal effects in humans after 
inhalation exposure to pyridine. 
Rats exposed to pyridine vapors at 5-10 mg/L for a single exposure period of about 40 minutes 
showed a decrease in glutamine level in the kidneys accompanied by an increase in ammonia excretion 
in the urine (Bolonova 1972, as cited in EPA 1978). 
2.2.1.3 Immunological Effects 
No studies were located regarding immunological effects in humans or animals after inhalation 




2. HEALTH EFFECTS 
2.2.1.4 Neurological Effects 
There are limited studies regarding neurological effects in humans after inhalation exposure to 
pyridine. In a case report on healthy adults, symptoms that developed following exposure to 
undetermined levels of pyridine vapors included headaches, giddiness, a desire to sleep, and 
quickening of pulse and respiration (Neff 1886). The study did not describe the concentration of 
pyridine or other exposure conditions such as duration of exposure. 
No studies were located regarding neurological effects in animals after inhalation exposure to 
pyridine. 
No studies were located regarding the following health effects in humans or animals after 
inhalation exposure to pyridine: 
2.2.1.5 Developmental Effects 
2.2.1.6 Reproductive Effects 
2.2.1.7 Genotoxic Effects 
In vitro genotoxicity studies are discussed in Section 2.4. 
2.2.1.8 Cancer 
No studies were located regarding cancer effects in humans or animals after inhalation 
exposure to pyridine. 
2.2.2 Oral Exposure 
2.2.2.1 Death 
No useful studies were located regarding death in humans after oral exposure to pyridine. 
The death of a 32-year-old man who had been receiving pyridine as an intermittent medication 
for the treatment of epilepsy has been reported (Pollock et al. 1943). Because other medications such 
as magnesium sulfate, sodium bromide, phenobarbital, and/or sodium dilantin were stated to be 
previous and continuing  medications for this patient and because the physical condition of this man at 
the start of pyridine treatment was not described, it is not possible to attribute this death specifically to 
pyridine exposure. 
Another case study reported the incident of a 29-year-old man who died within 2 days of 
ingesting approximately a half cup (about 125 mL) of pyridine during a syphoning accident (Helme 
1893). Upon admission to a hospital he was treated by the administration of demulcents (not otherwise 

























2. HEALTH EFFECTS 
chest, and a brandy enema which he was reported to have retained. It is not clear whether this medical 
intervention was of benefit to this man or possibly exacerbated an already serious situation. 
An LD50 of 1,580 mg/kg was reported in rats within 14 days following a single oral 
administration of pyridine (Smyth et al. 1951). No compound related deaths were reported in rats that 
received pyridine by gavage for 90 days at dosage levels up to 50 mg/kg/day (Anderson 1987). 
The LD50 value for rats in the acute-duration category and a NOAEL and LOAEL for death in 
rats in the intermediate-duration category are recorded in Table 2-2 and plotted in Figure 2-2. 
2.2.2.2 Systemic Effects 
The NOAEL values and all reliable LOAEL values for each systemic effect in each species and 
duration category are recorded in Table 2-2 and plotted in Figure 2-2. 
Respiratory Effects. No studies were located regarding respiratory effects in humans after oral 
exposure to pyridine. 
No compound-related gross or histopathological effects were observed in the lungs of rats that 
received pyridine by gavage for 90 days at dosage levels up to 50 mg/kg/day (Anderson 1987). 
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans 
after oral exposure to pyridine. 
No compound-related gross or histopathological effects were observed in the hearts of rats that 
received pyridine by gavage for 90 days at dosage levels up to 50 mg/kg/day (Anderson 1987). 
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans 
after oral exposure to pyridine. 
No compound-related gross or histopathological effects were observed in the gastrointestinal 
organs of rats that received pyridine by gavage for 90 days at levels up to 50 mg/kg/day (Anderson 
1987). 
Hematological Effects. No studies were located regarding hematological effects in humans 
after oral exposure to pyridine. 
No adverse effects on hematological parameters were noted in rats that received pyridine by 

























2. HEALTH EFFECTS 

Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after 
oral exposure to pyridine. 
No compound-related gross or histopathological effects were observed in the muscles or bones 
of rats that received pyridine by gavage for 90 days at levels up to 50 mg/kg/day (Anderson 1987). 
Hepatic Effects. No reliable studies were located regarding hepatic effects in humans after oral 
exposure to pyridine. Case studies have been reported in which two patients with epilepsy developed 
hepatic effects when treated with pyridine (Pollock et al. 1943). Co-administration of other 
medications including magnesium sulfate, sodium bromide, phenobarbital, and/or sodium dilantin to 
these patients before and during pyridine administration and the lack of information on their hepatic 
status previous to pyridine administration preclude a clear understanding of the role of pyridine in the 
observed effects. 
Pyridine exposure has been associated with hepatic effects in rats. In a 90-day study, female 
rats that received pyridine by gavage at dosage levels of 10 mg/kg/day and higher had significantly 
increased liver weights (Anderson 1987). Inflammatory hepatic lesions were found in 70% of male rats 
that received 50 mg/kg/day. Lesions included bile ductule proliferation, mixed peribiliary infiltrate, 
and enlarged vacuolated hepatocytes. These lesions were reported in 20% of females at 50 mg/kg/day. 
The NOAEL for liver effects in this study was 1 mg/kg/day. In a 3-month drinking water study, mice 
that received pyridine at dosage levels up to 380 mg/kg/day did not have significantly increased levels 
of malondialdehyde (a measure of lipid peroxidation) in their livers (Pinsky and Bose 1988). Hepatic 
effects, including liver enlargeness, vacuolization, and necrosis were also reported in early studies in 
which pyridine citrate in diets was administered to male rats for up to 4 months in a complex series of 
dietary experiments (Baxter 1948; Coulson and Brazela 1948; Baxter and Mason 1947). However, due 
to extreme variations in the dietary sources of vital nutrients and the failure to describe in detail the 
effects of the diets alone (without pyridine) on the liver of these rats, it is difficult to clearly attribute 
the observed effects to pyridine exposure. 
Renal Effects. No reliable studies were located regarding renal effects in humans after oral 
exposure to pyridine. Renal effects have been reported in case studies in which patients with 
convulsive disorders were given pyridine in conjunction with other medications such as magnesium
sulfate, sodium bromide, phenobarbital, and/or sodium dilantin (Pollock et al. 1943). Because of the 
coadministration of other substances and because the renal status of these patients before pyridine 




2. HEALTH EFFECTS 
No compound-related gross or histopathological effects were observed in the kidneys of rats 
that received pyridine by gavage for 90 days at dosage levels up to 50 mg/kg/day (Anderson 1987). 
Renal degeneration has been reported in studies in which pyridine citrate was administered in the diets 
of male rats for up to 4 months (Baxter 1948; Baxter and Mason 1947). However, despite variations in 
the composition of the diets and a lack of detailed information on the effects of those diets on the renal 
status of the test animals, it is possible to draw conclusions on the renal effects of pyridine 
administration from these studies. 
Dermal/Ocular Effects. No studies were located regarding dermal/ocular effects in humans 
after oral exposure to pyridine. However, congestion of the epiglottis, trachea, bronchi, lungs, 
esophagus, and stomach was reported in a case of accidental swallowing of half a cupful of pyridine 
which resulted in death (Helme 1893). This common finding of congestion would indicate that 
pyridine is irritating to mucous membranes of the gastrointestinal and respiratory systems. 
No compound-related dermal or ocular effects were observed in rats that received pyridine by 
gavage for 90 days at dosage levels up to 50 mg/kg/day (Anderson 1987). 
Other Systemic Effects. No studies were located regarding other systemic effects in humans 
after oral exposure to pyridine. 
In a go-day study, total body weight gain for male rats that received pyridine by gavage at 50 
mg/kg/day was significantly decreased from that of controls during weeks 8-12 of the study (Anderson 
1987). Significantly decreased weight gain was not found in any other dosage group. The NOAEL for 
this effect was 25 mg/kg/day. 
2.2.2.3 Immunological Effects 
No studies were located regarding immunological effects in humans or animals after oral 
exposure to pyridine. 
2.2.2.4 Neurological Effects 
No useful studies were located regarding neurological effects in humans after oral exposure to 
pyridine. A case study was reported in which a patient with epilepsy was reported to develop further 
neurological roblems, including a stuporous condition, slow and slurred speech, and slow reflexes 
during a 4-month oral treatment with pyridine as an anticonvulsive (Pollock et al. 1943). Co-
administration of other medications, including magnesium sulfate, sodium bromide, phenobarbital 
and/or sodium dilantin to this patient before and during pyridine administration, compounded by the 




























2. HEALTH EFFECTS 
No compound-related effects were observed in the brains of rats that received pyridine by 
gavage for 90 days at dosage levels up to 50 mg/kg/day (Anderson 1987). However, restlessness was 
observed in male rats following oral exposure at all dosage levels. 
In a 3-month drinking water study, mice that received pyridine at a dosage level of 380 mg/kg/day 
had significantly increased levels of malondialdehyde (a measure of lipid peroxidation) in the cerebellum
and striatum of their brains (Pinsky and Bose 1988). A marked but nonsignificant increase was measured in 
the cortex. The NOAEL for these effects was 38 mg/kg/day. 
The NOAEL value for neurological effects in the rat in the intermediate-duration category is 
recorded in Table 2-2 and plotted in Figure 2-2. 
2.2.2.5 Developmental Effects 
No studies were located regarding developmental effects in humans or animals after oral 
exposure to pyridine. 
2.2.2.6 Reproductive Effects 
No studies were located regarding reproductive effects in humans or animals after oral 
exposure to pyridine. 
2.2.2.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans after oral exposure to pyridine. 
No chromosomal damage was observed in a micronucleus test in which mice were 
administered a single dose of pyridine by gavage at doses up to 1,000 mg/kg (Harper et al. 1984). 
Other genotoxicity studies are discussed in Section 2.4. 
2.2.2.8 Cancer 
No studies were located regarding cancer effects in humans or animals after oral exposure to 
pyridine. 
2.2.3 Dermal Exposure 
2.2.3.1 Death 






2.2.3.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, or other systemic effects in humans or animals after dermal exposure 
to pyridine. 
Dermal/ocular Effects. In primary skin irritation studies in rabbits, application of pure 
pyridine has resulted in mild dermal irritation (scored 3 out of a possible 10) and moderate ocular 
irritation (scored 7 out of a possible 10) (Smyth et al. 1951). 
No studies were located regarding the following health effects in humans or animals after 
dermal exposure to pyridine: 
2.2.3.3 Immunological Effects 
2.2.3.4 Neurological Effects 
2.2.3.5 Developmental Effects 
2.2.3.6 Reproductive Effects 
2.2.3.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.4. 
2.2.3.8 Cancer 
No studies were located regarding carcinogenic effects in humans or 
animals after dermal exposure to pyridine. 
2.2.4 Other Routes of Exposure 
Because the available data on the toxicity of pyridine via inhalation, oral, and dermal exposure 
are extremely limited, studies conducted via intraperitoneal and subcutaneous exposures have also 
been considered. These studies are also limited in number and scope, and serve only to provide 
additional evidence that decreased weight gain is associated with exposure to this chemical. 
2.2.4.1 Death 
Acute LD50 values for subcutaneously administered pyridine in rats have been reported as 
1,000 mg/kg (Brazda and Coulson 1946) and 866 mg/kg (Mason et al. 1971). An LD50 of 1,200 mg/kg 
was reported for mice that received pyridine via intraperitoneal injection (Baxter and Mason 1947). 
Mortality rates for rats that received subcutaneous injections of pyridine twice weekly for a 
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2.2.4.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, or dermal/ocular effects in humans or animals after intraperitoneal or 
subcutaneous exposure to pyridine. 
Other Systemic Effects. No studies were located regarding other systemic effects in humans 
after intraperitoneal or subcutaneous exposure to pyridine. 
In rats that received subcutaneous injections of pyridine at 100 mg/kg/day twice weekly for a 
year, body weight was decreased 5%-16% below that of controls at the end of treatment. By 6 months 
after the termination of treatment, weights were comparable to control weights (Mason et al. 1971). 
2.2.4.3 Immunological Effects 
No studies were located regarding immunological effects in humans or animals after 
intraperitoneal or subcutaneous exposure to pyridine. 
2.2.4.4 Neurological Effects 
No studies were located regarding neurological effects in humans or animals after 
intraperitoneal or subcutaneous exposure to pyridine. 
2.2.4.5 Developmental Effects 
Abnormal chick development resulted from the injection of pyridine into eggs at very high 
levels (10 mg/egg or 20 mg/egg). Muscular hypoplasia occurred in 15% of chicks at the low dose and 
67% at the high dose. In addition, at the high dose, 4.9% of the chicks had defective beaks and 1.1% 
had short or twisted necks (Landauer and Salam 1974).  
2.2.4.6 Reproductive Effects 
No studies were located regarding reproductive effects in humans or animals after 
intraperitoneal or subcutaneous exposure to pyridine. 
2.2.4.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.4. 
2.2.4.8 Cancer 
No studies were located regarding cancer effects in humans after intraperitoneal or 
subcutaneous exposure to pyridine. 
18 
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There was no evidence of carcinogenicity due to pyridine administration in rats that received 
subcutaneous iniections at levels up to 100 mg/kg/day twice weekly for a year (Mason et al. 1971). 
2.3 TOXICOKINETICS 
2.3.1 Absorption 
2.3.1.1 Inhalation Exposure 
No studies were located regarding absorpt inhalation exposure to pyridine. ion in humans or 
anima1s after inhalation exposure to pyridine. 
2.3.1.2 Oral Exposure 
The available information indicates that orally administered pyridine is well absorbed by 
humans and animals. 
By 24 hours after ingestion of a single dose of 14C-pyridine at 0.05 mg/kg (administered in 
orange juice) by humans, approximately 67% of the administered 14C-label was recovered in the urine 
(D'Souza et al. 1980), indicating that at least 67% had been absorbed within that time period. In that 
same study, rats and guinea pigs that received 14C-pyridine at 7 mg/kg excreted 58% and 76%, 
respectively of the 14C-label in urine by 24 hours after administration, indicating absorption of at least 
those percentages of the administered dose. Rats administered 14C-pyridine at 7, 68, and 357 mg/kg 
excreted 58%, 13%, and 20%, respectively, of the 14C-label in their urine within 24 hours. The lower 
rate of excretion at higher doses suggests that the uptake of pyridine may involve nonlinear saturation 
kinetics. 
2.3.1.3 Dermal Exposure 
No studies were located regarding absorption in humans or animals after dermal exposure to 
pyridine. 
2.3.2 Distribution 
No quantitative studies were located regarding distribution in humans or animals after exposure 
to pyridine by the following routes: 
2.3.2.1 Inhalation Exposure 
2.3.2.2 Oral Exposure 
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2.3.3 Metabolism 
Some information on the metabolism of pyridine is derived from a study in which the N­
methylpyridinium ion was identified as a urinary metabolite of 14C-pyridine administered orally to 
humans, rats, and guinea pigs and via intraperitoneal administration to rats, guinea pigs, gerbils, 
hamsters, rabbits, and cats (D'Souza et al. 1980). In the 24-hour urine collection in humans, this 
metabolite was present at 9% of the administered dose, and in other species, levels of N- 
methylpyridinium varied widely with species, dose level, route of administration, and period of urine 
collection. Rats had a relatively low ability to methylate pyridine administered at 7 mg/kg either orally 
or via intraperitoneal injection, with 3.1% and 5.0%, respectively, of the administered dose recovered 
as the N-methylpyridinium ion in their urine in 24 hours. In guinea pigs, for comparison, these values 
were 31% and 31%, respectively, for oral and intraperitoneal administration. N-methylpyridinium
appears to be more toxic to rats and mice than pyridine itself (Brazda and Coulson 1946). No attempts 
were made to identify other metabolites of pyridine in this study. However, a subsequent study 
identified pyridine-Noxide as a urinary metabolite of all species tested in that study except rabbits and 
as accounting for nearly one-third of the total radioactivity (32% of the administered dose) in the 24­
hour urine from the human volunteers in that study (Damani et al. 1982). Other pyridine metabolites 
determined in these test animals included 2-pyridone, 3-hydroxypyridine, and 4-pyridone (human urine 
was not analyzed for these metabolites). Pyridine-N-oxide was also identified in the urine of hamsters, 
mice, rats, rabbits, ferrets, and guinea pigs after intraperitoneal administration of pyridine (Gorrod and 
Damani 1980). In an analysis of the data on urinary metabolites of pyridine reported in the early 
literature, EPA (1978) and Santodonato et al. (1985) have proposed the metabolic pathway by which 
N-methylation followed by ring hydroxylation or, alternatively, ring hydroxylation in the meta position 
would account for the observed metabolites. The presence of the N-methylpyridinium ion has been 
reported in the urine of humans, rats, guinea pigs, gerbils, mice, hamsters, and cats (D'Souza et al. 
1980). However, this pathway does not take into account the identification of pyridine-N-oxide and 
other metabolites in the urine of several species (humans, hamsters, rats, rabbits, mice, ferrets, and 
guinea pigs) after oral or intraperitoneal administration of pyridine (Damani et al. 1982; Gorrod and 
Damani 1980). A proposed metabolic pathway incorporating all above metabolites for pyridine is 
shown in Figure 2-3. 
2.3.4 Excretion 
2.3.4.1 Inhalation Exposure







2.3.4.2 Oral Exposure 
The only available information on excretion of orally administered pyridine is a study by 
D'Souza et al. (1980). In two humans who received 14C-pyridine at 0.05 mg/kg (administered in orange 
juice), approximately 67% of the administered 14C-label was recovered in the urine in a 24-hour 
period. In rats and guinea pigs administered 7 mg/kg, recovery was approximately 58% and 76%, 
respectively. These data indicate that urine is the major route of pyridine excretion in these species at 
these dose levels. No other information was provided. 
2.3.4.3 Dermal Exposure 
No studies were located regarding excretion in humans or animals after dermal exposure to 
pyridine. 
2.3.4.4 Other Routes of Exposure 
No data are available on the excretion of pyridine administered to humans via other routes of 
exposure. Several animal species were given intraperitoneal injections of 14C-pyridine in a study by 
D'Souza et al. (1980). In rats, guinea pigs, gerbils, mice, hamsters, rabbits, and cats that received doses 
of 7 mg/kg, levels of 14C-label recovered in urine (48-hour collection in cats, 72 hours in rabbits, 24 
hours in all other species) ranged from 75% of the administered dose in cats to 48% in rats. 
Comparisons of 14C-label excretion in the urine of rats and guinea pigs that received the same 
dose (7 mg/kg) of 14C-pyridine via oral or intraperitoneal administration indicated that values within 
each species were similar for both routes of administration; in rats, these values were 58% and 48%, 
respectively, of the administered dose, and in guinea pigs, these values were 31% and 31%, 
respectively, of the administered dose for both routes. 
2.4 RELEVANCE TO PUBLIC HEALTH 
As discussed in Section 2.2, the health effects resulting from exposure to pyridine have 
not been well studied. Other than LC50 data, there are no quantitative studies in humans or 
animals on the effects from inhalation exposure to pyridine, so no inhalation MRLs can be 
derived. By the oral route, there is limited evidence from case studies in humans (Pollock et 
al. 1943) that the liver is a target tissue for pyridine, and this is supported by a recent study in 
rats (Anderson 1987). However, it is not certain that hepatotoxicity is the most sensitive end 
point, since pyridine may cause neurobehavioral effects at lower exposure levels (Anderson 
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quantitative data on the NOAEL for hepatotoxic and neurotoxic effects, no oral MRLs can be derived 
at present. Similarly, no dermal MRLs can be calculated, due both to a lack of quantitative dermal 
dose-response data, and the lack of an appropriate methodology for development of dermal MRLs. 
Death. No deaths that are clearly attributable to pyridine have been reported in humans. The 
available information in animals does not suggest that lethality is a public health concern for exposure 
to pyridine via inhalation or the oral route. 
The death of a 32-year-old man who had been receiving pyridine as an oral medication for a 
convulsive disorder (epilepsy) has been reported (Pollock et al. 1943). Because other medications such 
as magnesium sulfate, sodium bromide, phenobarbital, and/or sodium dilantin were stated to be 
previous and continuing medications for this patient and because the physical condition of this man at 
the start of pyridine treatment was not described, it is not possible to attribute this death specifically to 
pyridine exposure. 
In another case study, a 29-year-old man died within 2 days of swallowing an estimated half-
cup of pyridine during a syphoning accident (Helme 1893). Medical intervention was immediate and 
rigorous and included the administration of demulcents (not otherwise described), milk, and brandy, 
application of mustard and linseed poultices to his throat and chest, and a brandy enema which he 
retained. It is not possible to assess the potential contribution of this treatment regimen to his rapid 
death. 
The levels of pyridine necessary to cause death in animals are very high. Reported l-hour 
validation LC50 values for rats were approximately 9,000 ppm (Vernot et al. 1977), and the acute oral 
LD50 value in rats was 1,580 mg/kg (Smyth et al. 1951). No compound-related deaths were reported in 
rats that received pyridine by gavage for 90 days at levels up to 50 mg/kg/day (Anderson 1987). 
Therefore, it appears to be unlikely that inhalation or ingestion of the low levels of pyridine that may 
be present in air, water, or food would present a concern for lethality in humans. A possible exception 
may be laboratory or industrial settings where accidental exposure to high levels of pyridine can occur. 
Systemic Effects. 
Hepatic Effects. Hepatic effects are the major potential health concern associated with exposure 
to pyridine. There is no clear evidence of hepatic effects associated with human exposure to pyridine. 
In a go-day gavage study in Sprague-Dawley rats, however, increased liver weight and inflammatory 
hepatic lesions, including bile duct proliferation, mixed peribiliary infiltrate, and enlarged vacuolated 
hepatocytes were found (Anderson 1987). These observations suggest that human exposure to pyridine 
via the oral route may pose a concern for adverse liver effects. It is important to note that this concern 
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evidence of hepatic effects from pyridine exposure has been previously reported in studies conducted 
more than 40 years ago. Pyridine citrate was administered to male rats (also Sprague-Dawley) for up to 
4 months in a complex series of dietary experiments that included variations in fat and carbohydrate 
sources and the levels of essential dietary nutrients such as certain amino acids (Baxter 1948; Baxter 
and Mason 1947; Coulson and Brazda 1948). The authors reported that the addition of pyridine to 
these diets resulted in hepatic enlargement, vacuolization, and necrosis. However, because of the other 
variations in the diet and lack of detail in reporting study results, it is difficult to interpret the findings 
of these experiments or to clearly attribute the observed effects to pyridine exposure. These studies do 
serve, however, to confirm the general conclusion of the Anderson (1987) study, which is that hepatic 
effects are of potential concern with oral exposure to pyridine and to suggest that exposed humans may 
also be at risk for hepatic effects. 
Renal Effects. There is no information on renal effects associated with human exposure to 
pyridine. Observations of degeneration of the renal tubular epithelium were reported in studies in 
which pyridine citrate was administered to male rats for up to 4 months (Baxter 1948). The numbers of 
rats used per group and duration of exposure were not clearly reported. However, variations in dietary 
composition (i.e., source and percentage of vital nutrients) did not contribute to the appearance of the 
observed lesions. 
The currently available data suggest that exposure to pyridine may be associated with potential 
renal effects in humans. 
Other Systemic Effects. There is no clear evidence of other systemic effects in association with 
human exposure to pyridine. However, decreased weight gain in developing rats during a go-day 
gavage study (Anderson 1987) suggests that this may be an area of concern associated with exposure 
to pyridine. During weeks 8-12 of this study, male rats consistently weighed 12%-14% less than 
controls, a difference that was statistically as well as clinically significant. Food consumption was not 
decreased in treated animals of either sex. This observation is supported by the results of a l-year study 
in which the body weights of rats that were administered pyridine at doses up to 100 mg/kg/day via 
subcutaneous injection were decreased 5%-16% below control values (Mason et al. 1971). Although 
these observations suggest that effects on body weight might also pose a potential health concern for 
humans exposed to pyridine, it is important to note that they are based on limited evidence. 
Immunological Effects. There are no studies of immunological effects in humans or animals exposed 
to pyridine via any route of exposure. 
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Neurological Effects. There are few studies of neurological effects in humans exposed to pyridine via 
any route of exposure. Pyridine is a central nervous system depressant. Neurological effects in man 
(nonpatients) have been noted by Pollock et al. (1943) and Neff (1886). Slow and slurred speech, slow 
reflexes, and a stuporous condition were reported to occur in an epilepsy patient who had been 
receiving other drugs in addition to pyridine (Pollock et al. 1943). Because of the existing disease state 
and the co-administration of other drugs, this information can only be viewed as suggestive evidence 
that exposure to pyridine can result in neurological effects in humans. Healthy adults, exposed to 
undetermined amounts of pyridine vapors, developed symptomatology which included some 
neurological effects. Included were slight temporal headaches, sensations approaching giddiness, a 
desire to sleep, and quickening of pulse and respiration (Neff 1886). 
No morphological effects were noted in the brains of rats that received pyridine by gavage for 
90 days at dosage levels up to 50 mg/kg/day (Anderson 1987). However, restlessness was noted in the 
male rats of all groups which received pyridine. This neurological effect was not observed in controls 
or female test rats. Lipid peroxidation was observed in selected areas of the brain of mice that received 
pyridine in their drinking water for 3 months at a dosage level of 380 mg/kg/day (Pinsky and Bose 
1988). The authors suggest that lipid peroxidation could lead to regionally selective neurotoxicity. The 
significance of this observation in relation to neurological function and/or morphology is not entirely 
clear. However, there is some evidence that neurological effects resulting from pyridine exposure via 
the inhalation and oral routes of exposure may be health concerns. 
Developmental Effects. There are no studies of developmental effects in humans or animals 
exposed to pyridine via the inhalation, oral, or dermal routes. However, abnormal chick development 
resulted from injection of pyridine into eggs at very high levels (l0-20 mg/egg). Muscular hypoplasia 
occurred in 15% of chicks at the low dose and 67% at the high dose. In addition, at the high dose, 4.9% 
of the chicks had defective beaks and 1.1% had short or twisted necks (Landauer and Salam 1974). 
Because of the test system and extremely high doses of pyridine used, the relevance of these 
findings to the potential effects of pyridine on human development is not clear. However, this study 
constitutes the only investigation of the effects of pyridine on prenatal development; therefore, 
these findings warrant some consideration. 
Reproductive Effects. No studies were located on reproductive effects of pyridine in humans or 
animals after any route of exposure. 
Genotoxic Effects. No studies were located concerning genotoxic effects of pyridine in humans after 
any route of exposure. The only available in vivo study in animals provides no evidence that exposure 
to pyridine is potentially 
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genotoxic. Negative results were reported in a micronucleus test in which single doses of pyridine were 
administered to mice by gavage at levels up to 1,000 mg/kg (Harper et al. 1984). 
In vitro genotoxicity data for pyridine, presented in Table 2-3, also indicate that pyridine does 
not show genotoxic potential. The results of tests for chromosomal aberrations using Chinese hamster 
ovary cells were negative (Ishidate and Odashima 1977) and sister chromatid exchange assays were 
weakly positive (Abe and Sasaki 1977). Results of assays using several strains of Salmonella 
tvphimurium have all been negative (Aeschbacher et al. 1989; Commoner 1976; Riebe et al. 2982; 
Seixas et al. 1982), as well as the pol A+/pol A- assay in Escherichia coli (Riebe et al. 1982). 
Cancer. No studies were located of carcinogenic effects of pyridine exposure in humans or 
animals by any route of exposure. 
2.5 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. 
They have been classified as markers of exposure, markers of effect, and markers of susceptibility 
(NAS/NRC 1989). 
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an 
interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a 
compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally 
the substance itself or substance-specific metabolites in readily obtainable body fluid(s) or excreta. 
However, several factors can confound the use and interpretation of biomarkers of exposure. The body 
burden of a substance may be the result of exposures from more than one source. The substance being 
measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can 
result from exposure to several different aromatic compounds). Depending on the properties of the 
substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route of exposure), 
the substance and all of its metabolites may have left the body by the time biologic samples can be 
taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly 
found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). 
Biomarkers of exposure to pyridine are discussed in Section 2.5.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other 
alteration within an organism that, depending on magnitude, can be recognized as an established or 
potential health impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or 
cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in 
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signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these 
markers are often not substance specific. They also may not be directly adverse, but can indicate 
potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by pyridine are 
discussed in Section 2.5.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an 
organism's ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be 
an intrinsic genetic or other characteristic or a preexisting disease that results in an increase in 
absorbed dose, biologically effective dose, or target tissue response. If biomarkers of susceptibility 
exist, they are discussed in Section 2.7, "POPULATIONS THAT ARE UNUSUALLY 
SUSCEPTIBLE." 
2.5.1 Biomarkers Used to Identify and/or Quantify Exposure to Pyridine 
There is currently no biomarker that is used to identify or quantify exposure to pyridine. 
Pyridine can be measured in blood and urine in humans and animals by gas chromatography 
(Audunsson 1988; Dubowski 1975). Also the rate of urinary excretion levels of 14C-labelled pyridine 
(Shaker et al. 1982) and its metabolite, the N-methylpyridinuim ion, have been measured (D'Souza 
et al. 1980). However, these methods cannot be used to measure pyridine exposure in humans. 
Pyridine-N-oxide can also be identified in the urine of several species, including mice, rats, rabbits, 
hamsters, guinea pigs and ferrets after intraperitoneal exposure to pyridine (Gorrod and Damani 1980). 
However, based on the currently available information, the levels of these substances in biological 
media cannot be used to calculate or estimate corresponding levels of exposure to pyridine. 
2.5.2 Biomarkers Used to Characterize Effect  Caused by Pyridine 
There are currently no subtle or sensitive biomarkers of effects associated with pyridine. 
Because of the limited amount of data available on this chemical, even the broad categories of toxicity 
have not yet been adequately characterized. 
2.6 INTERACTIONS WITH OTHER CHEMICALS 
There is currently no information on the interactions of pyridine with other chemicals. 
2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
No populations have been identified that are unusually susceptible to pyridine. However, 
persons with existing liver and kidney disease may be at increased risk of further liver and kidney 
damage, based on the results of studies in animals. 
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2.8 MITIGATION OF EFFECTS
 
This section will describe clinical practice and research concerning methods for reducing toxic effects 
of exposure to pyridine. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to pyridine. When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice. 
Central nervous system depression and hepatic and renal damage are the major effects observed 
following exposure to pyridine. Human exposure to pyridine may occur by inhalation, ingestion or by 
dermal contact. However, inhalation is the predominant route for acute exposures. General 
recommendations for reducing absorption of pyridine following exposure have included removing the 
exposed individual from the contaminated area and removing contaminated clothing, followed by 
washing the skin thoroughly with soap and water. If the eyes are exposed they are rinsed with water. 
Gastric lavage or administration of activated charcoal and a cathartic are common treatments following 
oral exposure (Spoerke 1991). Emetics are not recommended due to the hazard of aspirating gastric 
contents (Bronstein and Currance 1988). 
Information is limited regarding the retention of pyridine by the body, and so the need for methods for 
enhancing elimination is not clear. Excretion studies suggest that the compound is rapidly eliminated 
from the body (D'Souza et al. 1980). However, no information was located on the biological halflives 
of pyridine or its metabolites. No methods have been established for reducing the body burden 
following exposure to pyridine. 
The toxicity of pyridine has been attributed to its metabolites. If this is true, it could be possible to 
reduce toxicity by pharmacologically limiting metabolism, or shunting metabolism to routes that are 
less toxic than others. However, current knowledge of the metabolism of pyridine does not allow a full 
assessment of the net effect of interfering with that metabolism. Available studies suggest that 
methylation of pyridine may cause hepatic and renal injury by draining the labile methyl groups of 
choline and methionine thus producing an "intrinsic" deficiency of these substances (Baxter 1949; 
Baxter and Mason 1947). However, based on the metabolites found in urine in more recent excretion 
studies, methylation may not be a major metabolic route (D'Souza et al. 1980). Therefore, it's role in 
the overall toxicity of pyridine may be suspect. Urinary excretion of methylated pyridine accounted 
for only 5-12% of the administered dose in humans (D'Souza et al. 1980). On the other hand, urinary 
excretion of pyridine-N-oxide accounts for 32% of the administered dose, which is approximately half 
of the total radioactivity in the 24-hr urine from the human volunteers (Damani et al. 1982). The 
potential role of N-oxidation in the toxicity of pyridine has not been evaluated. Specific methods for 
reducing toxic effects cannot be established because of the limited information regarding the 
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2.9 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in 
consultation with the Administrator of EPA and agencies and programs of the Public Health Service) 
to assess whether adequate information on the health effects of pyridine is available. Where adequate 
information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), 
is required to assure the initiation of a program of research designed to determine the health effects 
(and techniques for developing methods to determine such health effects) of pyridine. 
The following categories of possible data needs have been identified by a joint team of 
scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs 
that, if met, would reduce or eliminate the uncertainties of human health assessment. In the future, the 
identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be 
proposed. 
2.9.1 Existing Information on Health Effects of Pyridine 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and 
animals to pyridine are summarized in Figure 2-4. The purpose of this figure is to illustrate the existing 
information concerning the health effects of pyridine. Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect. The dot does not imply anything 
about the quality of the study or studies. Gaps in this figure should not be interpreted as "data needs" 
information (i.e., data gaps that must necessarily be filled). 
As shown in Figure 2-4, studies of human exposure to pyridine are limited to case reports in 
which systemic effects, neurological effects, and death were associated with oral exposure. Existing 
animal studies are limited to lethality determinations via the inhalation and oral routes, dermal and 
ocular irritation data, and information on systemic and neurological effects from an intermediate-
duration study via the oral route. 
2.9.2 Data Needs 
Acute-Duration Exposure. There are currently no useful data available on humans exposed to 
pyridine for this duration period for any route of exposure. The only information available for animals 
are inhalation LC50 and oral LD50 values in rats (Smyth et al. 1951; Vernot et al. 1977) and primary 






not considered sufficient to derive an MRL for any route. Acute-duration studies conducted via the oral 
route would probably be most useful since persons living or working in the vicinity of hazardous waste 
sites are likely to be exposed via this route because pyridine has been found in the drinking water in 
these areas. Also, contamination of food and drinking water is possible in laboratories and industries 
where pyridine is being used. Inhalation data would also be useful for these populations and exposed 
workers. Toxicokinetic data are very limited for this chemical. A study using dermal exposure would 
be relevant to the safety of workers if absorption via this route were first demonstrated in other studies. 
Intermediate-Duration Exposure. There are currently no reliable data on humans exposed to 
pyridine for this duration period via any route of exposure. Data in animals are limited to a 90-day 
gavage study in rats in which the major adverse effects were hepatic lesions, neurological effects, and 
effects on weight gain were also seen (Anderson 1987). However, because there were no reliable 
supporting or confirmatory studies for this duration, the available data are not considered sufficient to 
derive an MRL for the oral or any other route. Toxicokinetic data are also extremely limited. An 
intermediateduration (90-day) study via the oral route would be useful since this is an important route 
of exposure for persons exposed via drinking water as a result of living or working in the vicinity of 
hazardous waste sites. The National Toxicology Program (NTP) is currently conducting a 14-week 
drinking water study in rodents (2 strains of rats and 1 strain of mice) which may provide valuable data 
to compare with information from the Anderson (1987) study which now serves as virtually the entire 
useful database for this duration period. A study conducted via dermal exposure would be especially 
useful if dermal absorption could first be demonstrated by other studies. 
Chronic-Duration Exposure and Cancer. There are no chronic-duration data available for 
humans or animals, and there are no toxicokinetic data for this exposure duration. Therefore, it is not 
possible to derive an MRL for any route for this duration. Chronic studies using the oral route would 
be useful, since chronic low-level exposure to pyridine via drinking water may occur in the vicinity of 
hazardous waste sites. Chronic inhalation studies are also necessary to characterize potential effects 
from breathing low levels of pyridine near these sites. 
There is also no information on the carcinogenic potential of pyridine in humans or animals. 
Chronic-duration studies conducted via any route of exposure should assess this potential effect. As 
stated previously, exposure via the oral route is probably the most relevant to persons living or 
working in the vicinity of hazardous waste sites. Inhalation exposure to pyridine in contaminated air is 
also a route of concern for persons living and working near these sites. 
Genotoxicity. The currently available in vivo and in vitro studies do not indicate that pyridine is 
potentially genotoxic (Abe and Sasaki 1977; Aeschbacher et al. 1989; Commoner 1976; Harper 
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et al. 1984; Ishidate and Odashima 1977; Riebe et al. 1982; Seixas et al. 1982). Further studies in this 
area do not appear to be warranted unless metabolic studies indicate the generation of a potentially 
genotoxic metabolite, an alkylating agent, and/or 
a compound that might be capable of DNA binding. 
Reproductive Toxicity. There is currently no information on the effects of pyridine on 
reproductive parameters in humans or animals via any route of exposure. In any further studies 
conducted for any duration period and via any route of exposure, it would be useful to investigate the 
potential doseresponse relationship of exposure to pyridine on a number of end points, including sperm 
count, sperm morphology, and reproductive organ pathology. If the reproductive system were 
identified as a target, studies to assess reproductive function would be useful. This information would 
be valuable in helping to assess the impact of pyridine on the reproductive capacity of exposed workers 
and persons living and working in the vicinity of hazardous waste sites. 
Developmental Toxicity. There are currently no available studies on the developmental effects 
of pyridine via inhalation, oral, or dermal exposure in humans or animals. The relevance of effects 
observed on the development of chick embryos when extremely high levels of pyridine were injected 
into eggs (Landauer and Salam 1974) is unknown; these observations suggest that this may be an area 
in which further study is warranted. Studies to assess the potential developmental effects of exposure 
to pyridine would therefore, be useful. Chronic studies using the oral and inhalation routes would 
probably be the most helpful in assessing the potential risks to the offspring of persons exposed in the 
vicinity of hazardous waste sites. 
Immunotoxicity. There are currently no data in humans or animals on the effects of pyridine 
on the immune system via any route of exposure. Immunological assessments, including analysis of 
peripheral blood components and effects on lymphoid tissue, would be a valuable component of any 
intermediate- or chronic-duration studies conducted in the future via any route of exposure. This would 
be helpful in developing a dose-response relationship and assessing the potential risks of persons 
exposed in the workplace and in the vicinity of hazardous waste sites. 
Neurotoxicity. There are currently few data on the effects of pyridine on the nervous 
system of humans via any route of exposure. However, pyridine is a central nervous depressant 
and has been used to treat epileptic patients (Pollock et al. 1943). The only information in 
animals is a 90-day gavage study in rats (Pinsky and Bose 1988) in which no morphological 
effects were noted in brain tissue and a 3-month drinking water study in mice which resulted in 
increased levels of lipid peroxidation in brain tissue, Restlessness in male rats was observed in 
the 90 day gavage study (Anderson 1987). In any further studies conducted via any route of 
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neurological effects, including histopathological changes as well as clinical manifestations in order to 
assess the potential neurotoxic effects of exposure to pyridine in the workplace or in the vicinity of 
hazardous waste sites. A study currently being conducted by the firm of Arthur D. Little to assess the 
neurological effects of short-term oral exposure to pyridine in mice should provide useful information. 
Epidemiological and Human Dosimetry Studies. No epidemiological studies have been 
identified for populations exposed to pyridine. These studies would be useful in assessing potential 
adverse effects in humans. In any such studies, points of greatest interest based on the results of 
previous studies in animals appear to be effects on liver and body weight and any developmental 
abnormalities in the offspring of exposed persons. Neurological, dermal/ocular, and renal observations 
would also be of interest. Similarly, human dosimetry studies of these populations would be useful in 
associating pyridine levels with the reported effects. 
Biomarkers of Exposure and Effect. Measurement of pyridine or its metabolites, N­
methylpyridinium, or pyridine-N-oxide, in blood or urine may provide an adequate qualitative 
indication of recent exposure to pyridine (Audunsson 1988; Dubowski 1975; Gorrod and Damani 
1980). However, very little information is currently available on these measurements in humans or 
animals, especially for N-methylpyridinium. The development of methods that could be used to 
calculate or estimate levels of exposure to pyridine from the levels of these substances in biological 
fluids would be extremely useful.  
There are currently no subtle or sensitive biomarkers of effects known for pyridine. After 
pyridine toxicity has been more fully studied, further research to identify biomarkers of pyridine 
effects would be helpful in assessing possible health impacts of pyridine around hazardous waste sites.  
Absorption, Distribution, Metabolism, and Excretion. There is currently very little 
information on the toxicokinetics of pyridine. A study in humans, rats, and guinea pigs indicates that it 
can be absorbed by these species via the oral route (D'Souza et al. 1980). Estimates of the extent of 
absorption via the inhalation and dermal routes and calculations of the rates of absorption via all three 
routes would be useful in helping to compare relative potential risks due to the presence of pyridine in 
various environmental media. In addition, information on potential determinants of absorption (dose 
level, nutritional status, etc.) would also be helpful in assessing potential absorption by exposed 
humans and the consequent relevance of conducting further toxicity tests in animals by the inhalation 
or dermal routes.  
There are no distribution data available for pyridine in humans or animals. The use of multiple 
species and a comparison of tissue levels of pyridine associated with multiple dose levels via each 
route of exposure would be useful in helping to assess the likelihood that pyridine would reach 
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It would be useful to fully elucidate the metabolic pathway for orally administered pyridine in 
mammalian species. Further studies via the oral route may provide data on potentially toxic  
intermediates, including evidence for the generation of alkylating agents. It would also be useful to 
collect data on urinary metabolites identified during inhalation or dermal administration of pyridine. 
Available data indicate that in humans, rats, and guinea pigs, orally administered pyridine 
and/or its metabolites are excreted mainly in the urine (D'Souza et al. 1980). However, complete 
balance studies to account for all of the pyridine administered are not available. Data on fecal and 
breath excretion associated with the oral route and with all routes of excretion after inhalation and 
dermal administration would be useful.  
Comparative Toxicokinetics. The toxicokinetic studies available in both humans and animals 
are limited and it is not possible to determine if there are any major differences in the kinetics of this 
compound across species. It would be useful to investigate patterns of distribution to identify target 
organs and to measure rates of excretion in several species and to identify blood metabolites in humans 
and animals in order to confirm these assumed relationships. Studies in this area would also be helpful 
in putting the results of all available toxicity studies into perspective in terms of their relevance to the 
potential human health effects of pyridine under similar conditions of exposure.  
Mitigation of Effects. Recommended methods for the mitigation of acute effects of pyridine 
include administration of oxygen if exposure is by inhalation, flushing with water if exposure is to skin 
or eyes, and gastric lavage or administration of activated charcoal if exposure is oral (Bronstein and 
Currance 1988; Spoerke 1991). No information was located concerning mitigation of effects from
lower-level or longer-term exposure to pyridine. Further information on techniques to mitigate such 
effects would be useful in determining the safety and effectiveness of possible methods for treating 
pyridine-exposed populations surrounding hazardous waste sites. 
2.9.3 On-going Studies 
A research project is now in progress investigating the neurological effects of short-term
exposure to pyridine via gavage in the rat (CCTTE 1988). These tests are being conducted by the firm
of Arthur D. Little and are sponsored by EPA's Office of Solid Waste. No other details are currently 
available for this study. 
In addition, NTP is completing the prechronic phase of studies of pyridine (includes 14- and 
90-day studies). The objective of these studies is to determine doses for the chronic toxicity and 







3. CHEMICAL AND PHYSICAL INFORMATION 
3.1 CHEMICAL IDENTITY 
Table 3-1 lists common synonyms, trade names, and other pertinent identification information 
for pyridine. 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 





4. PRODUCTION, IMPORT, USE, AND DISPOSAL 
4.1 PRODUCTION 
Pyridine is produced either by isolation from natural sources such as coal, or through chemical 
synthesis (HSDB 1989). Pyridine is produced by the fractional distillation of coal-tar residues (HSDB 
1989; NSC 1978; Santodonato et al. 1985) in which 1 ton of coal produces 0.07-0.21 pounds of 
pyridine bases of which 57% is pyridine (Santodonato et al, 1985). Synthetically produced pyridine is 
currently the more important source of pyridine for commercial uses (Santodonato et al. 1985). Small 
amounts of pyridine are synthesized from acetaldehyde, formaldehyde, and ammonia with a fluidized 
silica-alumina catalyst, followed by fractionation to isolate the pyridine (Harper et al. 1985; HSDB 
1989; NSC 1978). 
Pyridine is produced from natural sources by Crowley Tar Products of Stow, Ohio, and 
Oklahoma City, Oklahoma (Harper et al. 1985; HSDB 1989; SRI 1986, 1987, 1988). Pyridine is 
synthetically produced by two companies, the Nepera Chemical Co. of Harriman, New York and the 
Reilly Tar and Chemical Corporation of Indianapolis, Indiana (Harper et al. 1985; SRI 1986, 1987, 
1988). 
Current volumes of pyridine produced in the United States were not located (HSDB 1989). 
Production volumes steadily increased from 1945 (844 metric tons) through 1968 (3,366 metric tons), 
and the estimated 1985 production volume of pyridine was 6,800 metric tons (Santodonato et a1. 
1985). Production is expected to continue at a steady annual increase of l-28 depending upon economic 
conditions (Santodonato et al. 1985). The U.S. production capacity for synthetic pyridines (pyridine 
and pyridine derivatives) is estimated to be 27,216 metric tons (Santodonato et al. 1985). 
Harper et al. (1985) estimated the 1982 consumption of pyridine in the United States at 5,400-7,500 
metric tons. Facilities that manufacture or process pyridine are shown in Table 4-l. 
4.2 IMPORT/EXPORT 
No information was located regarding the current import volume of pyridine. The 1973 import 
volume was 4.5 metric tons (HSDB 1989). The United States exports 50% of the pyridines it produces 
(Harper et al. 1985). It is not clear whether this includes pyridine derivatives in addition to pyridine. 
In 1975, exports of pyridine were 341 metric tons (HSDB 1989). No data were located regarding 
current export volumes. 
4.3 USE 
Pyridine is used directly in the denaturation of alcohol (ACGIH 1986; HSDB 1989; NSC 1978) 
and as a solvent in paint and rubber preparation (ACGIH 1986; HSDB 1989; NSC 1978) and in research 










4. PRODUCTION, IMPORT, USE, AND DISPOSAL 
produced today is used as an intermediate in making various insecticides and herbicides for 
agricultural applications (ACGIH 1986; Harper et al. 1985; Santodonato et al. 1985). Approximately 
20% goes into the production of piperidine (Harper et al. 1985; Santodonato et al. 1985) which is 
commercially significant in the preparation of chemicals used in rubber vulcanization and 
agriculture (NSC 1978). Pyridine is also used as an intermediate in the preparation of drugs 
(antihistamines, steroids, sulfa-type and other antibacterial agents) dyes, water repellents, and 
polycarbonate resins (ACGIH 1986; Harper et al. 1985; NSC 1978; Santodonato et al. 1985). Pyridine 
is also approved by the Food and Drug Administration (FDA) for use as a flavoring agent in the 
preparation of foods (Harper et al. 1985; HSDB 1989) (for additional information about pyridine in 
foods, see Chapter 5). 
4.4 DISPOSAL 
Waste pyridine, when present as a constituent of a commercial chemical product or chemical 
intermediate, is considered to be a hazardous waste, as is any residue, soil, water, or other debris 
resulting from the clean-up of this waste. Disposal of these materials must be managed according to 
state and federal regulations (HSDB 1989). Restrictions that apply to the disposal of waste pyridine are 
listed in Chapter 7. 
Current practices for the disposal of waste pyridine include rotary kiln incineration at 820° ­
1,600°C (HSDB 1989). Waste pyridine is a potential candidate for liquid injection incineration (650° ­
1,600°C) or fluidized bed incineration at a temperature range of 450°-980°C (HSDB 1989). 
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5.1 OVERVIEW
 
Pyridine is an organic liquid with an unpleasant odor; it is very soluble in water. It is released 
to the environment from industrial sources that manufacture and use it and as fugitive emissions from 
facilities such as coal gasification and oil shale processing. Pyridine may be removed from the 
atmosphere by photooxidation or wet deposition (precipitation). Pyridine in water is unlikely to 
volatilize appreciably, but may sorb to soils and sediments or biodegrade. Bioconcentration of pyridine 
in aquatic organisms is not likely to be important. 
Pyridine has rarely been detected in ambient air, water, or soil, except in the vicinity of 
industrial sources. Several foods may contain pyridine, and ingestion of these foods is the most likely 
route of pyridine exposure for the general population. Occupational exposure to pyridine may be high. 
Populations living in the vicinity of hazardous waste sites where pyridine has been detected may also 
be exposed. The EPA has identified 1,177 NPL sites. Pyridine has been found at 4 of the sites 
evaluated for this chemical. However, we do not know how many of the 1,177 NPL sites have been 
evaluated for this chemical. As more sites are evaluated by the EPA, the number may change (View 
1989). The frequency of these sites within the United States can be seen in Figure 5-l. 
5.2 RELEASES TO THE ENVIRONMENT
 Manufacturers, processors, and users of pyridine are required to report quantities of releases of 
this substance to environmental media annually (EPA 1988a). According to the SARA Section 313 
Toxics Release Inventory (TRI), an estimated total of 635,374 pounds of pyridine were released to the 
environment from manufacturing and processing facilities in the United States in 1987 (TRI 1989). 
The TRI data should be used with caution since the 1987 data represent first-time reporting by these 
facilities. Only certain types of facilities were required to report. This is not an exhaustive list. The 28 
facilities reporting releases in 1987 are presented in Table 5-l. 
Additional releases of pyridine may occur from oil shale processing and coke oven facilities, 
but these releases are not included in the TRI. Releases of pyridine relevant to specific media are 
discussed below. 
5.2.1 Air 
Pyridine is released to the atmosphere from facilities that manufacture and use this compound 
and from oil shale processing and coke oven facilities. Releases of an estimated 298,438 pounds of 
pyridine to air from domestic industrial sources were reported in 1987 (TRI 1989). Atmospheric 
emissions of pyridine from shale oil waste waters ranged from 0.44 to 30 µg/mL of wastewater 
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5.2.2 Water 
Releases of pyridine to ambient waters have been reported. Industrial releases to surface water 
and groundwater (underground injection) reported in 1987 were estimated to be 4,630 pounds and 
303,650 pounds, respectively (TRI 1989). In addition, 209,880 pounds of pyridine were disposed of in 
publicly owned treatment works (POTWs) in 1987 (TRI 1989). Some fraction of the quantity treated at 
POTWs is probably released to the environment. Pyridine was detected in one of two oi1 shale 
processing effluents at a concentration of 152 µg/L (ppb), but not in coal gasification plant effluents 
(Pellizzari et al. 1979). It was also detected in effluents from coke-oven quenching operations at 11 
mg/L (EPA 1982b) and detected, but not quantified, in four industrial effluents (Shackelford and Keith 
1976). Pyridine was also found in oil-shale retort water in Australia at a concentration of about 5 mg/L 
(Dobson et al. 1985). 
Data from the Contract Laboratory Program (CLP) Statistical Database indicate that none of 
the hazardous waste sites sampled were positive for pyridine in surface water or groundwater (Eckel 
1990). 
5.2.3 Soil 
Pyridine releases to land from industrial sources totalled an estimated 28,656 pounds in 1987 
(TRI 1989). Additional releases of pyridine to soil may occur from spillage of oil shale waste waters 
on land surfaces (Leenheer and Stuber 1981). No other information was located on pyridine releases to 
soil. Pyridine was not detected in soil samples from hazardous waste sites (Eckel 1990). 
5.3 ENVIRONMENTAL FATE 
5.3.1 Transport and Partitioning 
Pyridine exists in the atmosphere as a vapor. Its vapor pressure is approximately 0.027 atm 
(20.6 mmHg) at 25°C (Chao et al. 1983). Because of its high water solubility, a large fraction of vapor-
phase pyridine released to the atmosphere would tend to dissolve in water vapor (such as clouds and 
rain drops). A Henry's law constant estimates the tendency of a chemical to partition between its vapor 
state and water. The Henry's law constant for pyridine was measured as l.lxl0-5 atm-m3-mole-1 at 25°C 
for aqueous solutions (5 mg/L) (Hawthorne et al. 1985). The magnitude of this value indicates that 
much of the pyridine in the atmosphere is removed by wet deposition (precipitation). 
Pyridine is highly soluble in water (Jori et al. 1983). The magnitude of Henry's law constant 
(l.lxl0-5 atm-m3-mole-1 for aqueous solutions) suggests that pyridine in water will not volatilize into the 
atmosphere quickly. In addition, the equilibrium partitioning of pyridine between water and air was 
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found to be influenced by the pH of the water; a decrease in pH resulted in less partitioning from 
solution (Hakuta et al. 1977). The rate of pyridine volatilization from water has not been 
experimentally measured. 
Pyridine in water may partition to soils and sediments to an extent that depends on the pH of 
the water, and to a lesser extent, the organic-carbon content of the soil. Pyridine is a weak organic base 
in solution; its ionization constant is 5.23x10-6 at 20°C (Albert et al. 1948). Consequently, pyridine is 
predominantly in a cationic electrolyte form (pyridinium ion) in acidic solutions, whereas it is a neutral 
molecule in alkaline media. 
The extent of pyridine adsorption by pure-clay minerals was greatest in 
the pH range of 4-5.5, whereas adsorption was negligible in alkaline solutions (pH greater than 7) 
(Baker and Luh 1971). The magnitude of pyridinium adsorption was correlated with the cation-
exchange capacity of the clays. The rate of pyridinium desorption from the clays was slower than that 
of adsorption (Luh and Baker 1971). 
Pyridine was weakly adsorbed by sandstone at 38°C (Donaldson et al. 1975), but these authors 
did not report any pH measurements. Pyridine adsorption by an alkaline soil was negligible (Felice et 
al 1984); Zachara et al. (1987) also found that pyridine adsorption was more significant in acidic soils 
because of salt formation. 
The extent of adsorption of neutral organic molecules by soils is often correlated with the 
organic-carbon content of the soil (Hassett et al. 1983). When adsorption is expressed as a function of 
organic-carbon content, an organic carbon/water partition coefficient (Koc) can be calculated and may 
be used to classify the relative mobility of the chemical in soil. Based on its octanol-water partition 
coefficient (Table 3-2), an estimated Koc for pyridine is 7 (Roy and Griffin 1985). An experimentally 
derived Koc of about 40 can be calculated from the adsorption data in Zachara et al. (1987). As 
compared with Koc values listed for other compounds, these low Koc values suggest that pyridine is 
very highly mobile in soil, whereas pyridine as pyridinium will be less mobile, particularly in acidic 
soils. 
Pyridine may not partition to organisms in water. An octanol/water partition coefficient (KoW) 
estimates the likelihood of a chemical to partition to organisms in an aquatic environment. Octanol is 
believed to best imitate the fatty structures in plants and animal tissues (Kenaga and Goring 1980). The 
Koc of pyridine has been measured as 4 (Leo et al. 1971). This low value indicates that pyridine will 
not partition to fatty tissues in plants or animals. 
A bioconcentration factor (BCF) relates the concentration of a chemical in the tissues of aquatic 
organisms to the concentration of the chemical in the media in which they live. BCFs for pyridine have 
not been experimentally measured, but they may be less than 5, based on the empirical regressions of 
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Kenaga (1980) and Neely et al. (1974). These low BCFs suggest that pyridine is probably not 
bioconcentrated by aquatic plants and animals and therefore probably not biomagnified in terrestrial or 
aquatic food chains. 
5.3.2 Transformation and Degradation 
5.3.2.1 Air 
Atmospheric pyridine may be slowly photodegraded by hydroxyl radicals in the troposphere. 
The rate constant for this reaction at 23°C has been measured as 5x10-13 cm3/molecule-s, and the 
estimated atmospheric life time of pyridine may range from 23 to 46 days, depending on the 
concentration of hydroxyl radicals (Atkinson et al. 1987). Reaction by-products were not studied. It 
appears that the rate of ozone-initiated decay of pyridine is too slow to be an important mechanism for 
removing pyridine from the atmosphere. The decay rate of pyridine by ground-state oxygen (O(3P)) 
has been measured as 1.7x10-13 cm3/molecule-s (Mani and Sauer 1968). If the mean concentration of 
ground-state oxygen radicals is 5x10-4 molecules/cm3 (Cupitt 1980), then the half-life of this reaction 
(2.6 years) may also be too slow to be important. 
5.3.2.2 Water 
Biodegradation may be the most important mechanism that can degrade pyridine in water. 
Pyridine may oxidize in water, but the reactions are very slow. The rate constant for pyridine oxidation 
by alkylperoxy radicals (RO2) was estimated as approximately 0.67/M-s at 50°C (Mill et al. 1979). 
Because of the low concentration of these radicals in photolyzed natural waters, the half-life of this 
reaction may be on the order of decades. The rate constant for hydroxyl radical-initiated decay in water 
has been measured as 1.8x109/M-s at 21°C, pH 7 (Dorfman and Adams 1973). radicals is 10-17 mole/L 
(Mill et al. If the mean concentration of hydroxyl 1979), the half-life of this reaction would be about 
1.2 years. No information was located that suggests that pyridine hydrolyzes in water nor should it be 
anticipated from its chemical structure. 
Most pyridine biodegradation studies have been concerned with transformations in soils and 
sewage sludges (see Section 5.3.3). In a study of pyridine biodegradation in unfiltered river water, the 
rate of removal depended on the initial concentration of pyridine, but in general, at lower 
concentrations (less than 20 mg/L), pyridine degradation was virtually complete in 8 days or less 
(Cassidy et al. 1988). No information concerning the microorganisms present in the water was given, 
but this study suggests that biodegradation may be a much more rapid mechanism for the removal of 
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5.3.2.3 Soil 
It is very likely that pyridine biodegrades in soils and sewage sludges, but the rate and extent of 
the process is uncertain. Pyridine has been found to biodegrade readily in laboratory-screening tests 
(Gerike and Fischer 1979, 1981; Ruffo et al. 1984). For example, about 94%-100% of the pyridine 
added to municipal wastewater biodegraded in 2-21 days, depending on the specific test procedure 
used. Other studies have reported that pyridine biodegraded in sewage water or sludge, but that the 
process was slow (Battersby and Wilson 1989; Cooper and Catchpole 1973; Ettinger et al. 1954; 
Gomolka and Gomolka 1978; Malaney 1960). For example, pyridine was found to be only partially 
degraded in dilute sewage sludge, and the process required a month before significant removal was 
detected (Battersby and Wilson 1989). 
There is evidence that pyridine can be biodegraded in soil. A branching bacteria 
(Proactinomyces) that can utilize pyridine as a sole-source of carbon and nitrogen, and energy has been 
isolated (Moore 1949). Pyridine was biodegraded in an aqueous extract of a garden soil, but the 
process was slow (Naik et al. 1972). Complete degradation under aerobic conditions required 
66-170 days, whereas l-2 months were required under anaerobic conditions. However, in a soil 
incubated with low concentrations of pyridine, the compound was completely degraded in about 8 days 
(Sims and Sommers 1985). The halflife of the process was approximately 3 days.  
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
5.4.1 Air 
Pyridine has not been detected in ambient outdoor air, except in the vicinity of industrial 
sources. Pyridine was not found in rural or urban air (Hawthorne and Sievers 1984; Shah and 
Heyerdahl 1988). However, pyridine was detected at a concentration of 13 µg/m3 in air in the vicinity 
of an oil shale wastewater facility (Hawthorne and Sievers 1984; Shah and Heyerdahl 1988). Pyridine 
was also present in indoor air at the same oil shale facility at a concentration of 41 µg/m3 (Hawthorne 
and Sievers 1984). The concentration of pyridine in indoor air contaminated with cigarette smoke may 
be as high as 16 µg/m3 (Brunnemann et al. 1991). 
Pyridine has been detected in workplace air at pyridine manufacturing plants and chemical 
plants using pyridine as an intermediate at time-weighted average (TWA) concentrations ranging from
0.02 to 3.2 mg/m3 (EPA 1982b). 
5.4.2 Water 
Pyridine is rarely detected in ambient waters. It was present in surface water of the Cuyahoga 
River in Ohio (IJC 1983). The compound was not detected in groundwater samples in Wyoming 
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groundwater 15 months after completion of coal gasification activities at a Wyoming site at 
concentrations ranging from 0.82 to 53 ppb (Stuermer et al. 1982). Pyridine was detected in 2 of 17 
drinking water concentrates (Lucas 1984). 
5.4.3 Soil 
No information was located on pyridine concentrations in ambient soils. Pyridine was detected 
in creosote-contaminated sediments in Puget Sound, Washington at a concentration of 0.22 µg/g 
(Krone et al. 1986). 
5.4.4 Other Environmental Media 
Pyridine may be present in foods from both natural and anthropogenic sources. Pyridine was 
detected among the natural volatile components of several foods, including fried chicken, Beaufort 
cheese, sukiyaki, fried bacon, and frozen mango (Dumont and Adda 1978; Ho et al. 1983; MacLeod 
and Snyder 1.988; Shibamoto et al. 1981; Tang et al. 1983). The concentration was reported only for 
mango at 1.0 µg/g (MacLeod and Snyder 1988). Pyridine is approved by the Food and Drug 
administration (FDA) for use as a flavoring agent (Table 7-l) and, therefore, may be present in other 
foods as well. Pyridine has also been identified as a component of tobacco smoke (Curvall et al. 1984; 
Florin et al. 1980; Riebe et al. 1982) and is a coffee aroma constituent (Aeschbacher et al. 1989). 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
Humans may be exposed to pyridine by inhalation, ingestion, or dermal contact. However, in 
the United States the general population is most likely to be exposed to pyridine by the ingestion of 
foods naturally containing this compound or, possibly, by inhalation of tobacco smoke. EPA (1978) 
reported that total pyridine is estimated to be ingested in the United States at about 500 mg/year, per 
person, mainly from food. The presence of pyridine in expired air is not necessarily an indicator of 
exposure to this chemical since pyridine has been detected in the expired air (detection limits not 
specified) of nonsmoking subjects described as prediabetic (i.e., nine offspring of diabetic parents and 
five subjects having one diabetic parent and several diabetic relatives) (Krotoszynski and O'Neill 
1982). Pyridine was not detected in the expired air of 20 nonsmoking control (nondiabetic) or 28 
diabetic subjects. 
The greatest potential for exposure to pyridine occurs in the workplace. 
Occupational exposures, usually by inhalation or dermal absorption, may occur during pyridine 
production or its use as a chemical intermediate or solvent (Santodonato et al. 1985). Additional 
exposures may occur at coke-oven and oil-shale processing facilities. Reported workplace TWA 
concentrations range from 0.02 to 3.2 mg/m3 (ppm) (EPA 1982b), but these data do not include 
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to pyridine will not exceed 3.2-16 mg/m3, except for possible brief exposures to higher concentrations 
(Santodonato et al. 1985). The National Institute for Occupational Health and Safety (NIOSH) 
estimated that the number of workers exposed to pyridine increased from about 29,000 during the early 
1970s (NOHS 1990) to about 41,000 during the early 1980s (NOES 1990). These estimates also do not 
include workers at coke-oven plants. Neither the NOHS nor the NOES databases contain information 
on the frequency, concentration, or duration of exposure of workers to any of the chemicals listed 
therein. These surveys provide only estimates of the number of workers potentially exposed to 
chemicals in the workplace.  
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Workers in industrial facilities that manufacture, use, or produce fugitive emissions of pyridine 
have the highest potential for exposure to this compound. Other populations with potentially higher 
than average exposure are those living in the vicinity of these facilities or of hazardous waste sites 
at which pyridine has been identified. 
5.7 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in 
consultation with the Administrator of EPA and agencies and programs of the Public Health Service) 
to assess whether adequate information on the health effects of pyridine is available. Where adequate 
information is not available, ATSDR, in conjunction with the NTP, is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of pyridine. 
The following categories of possible data needs have been identified by a joint team of 
scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs 
that, if met, would reduce or eliminate the uncertainties of human health assessment. In the future, the 
identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be 
proposed. 
5.7.1 Data Needs 
Physical and Chemical Properties. Most of the physical/chemical properties required to 
predict the environmental fate and transport of pyridine have been measured. However, it appears that 
the volatility and sorption of pyridine from water varies considerably with the pH of the water 
(Baker and Luh 1971). Additional data on the effect of pH on the Henry's law constant, volatilization 
rate, and Koc would be useful to predict more accurately the environmental fate of pyridine. 
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Production, Import/Export, Use, and Disposal. Information is generally available regarding 
the production, use, and disposal of pyridine in commercial facilities (Harper et al. 1985; HSDB 1989). 
The production locations, major uses, and disposal methods have been identified, and land disposal of 
pyridine is restricted by EPA. However, current production, import, and disposal volumes were not 
located. Releases from manufacturing and use facilities are reported in the TRI, but fugitive emissions 
from cokeoven and oil-shale processing facilities have not been reported. These data would be useful 
in evaluating both occupational exposures and exposures of the populations living in the vicinity of 
these facilities. 
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. 
Section 11023, industries are required to submit chemical release and off-site transfer information to 
the EPA. The Toxics Release Inventory (TRI), which contains this information for 1987, became 
available in May of 1989. This database will be updated yearly and should provide a list of industrial 
production facilities and emissions. 
Environmental Fate. The available data are insufficient to predict accurately the 
environmental fate of pyridine. Pyridine most likely partitions to soils and sediments and from the 
atmosphere to water vapor. Additional data regarding the Koc of pyridine, especially in nonacidic 
environments, would be useful in confirming the likelihood of pyridine partitioning among 
environmental media. 
Data on transport and degradation are limited. Data on the composition and fate of the products 
of the atmospheric photodegradation of pyridine would enhance our understanding of the atmospheric 
fate of this compound, and additional studies on the biodegradation of pyridine in water and soil would 
be helpful in evaluating the fate of pyridine in these media. 
Bioavailability from Environmental Media. Pyridine is very soluble in water (Sax and Lewis 
1987). Human and animal data indicate that it is well absorbed by the oral route (D'Souza et al. 1980). 
It is expected to be available when it is present in natural waters. Under acidic conditions, it will 
adsorb to soils and sediments to some degree (Baker and Luh 1971). However, ingestion of soil-bound 
pyridine is an unlikely route of exposure. Information on dermal absorption from water would be 
useful in assessing the potential effects of recreational use of natural waters contaminated with 
pyridine. Information on absorption of inhaled pyridine released to the air would also be useful in 
assessing its bioavailability from that medium. 
Food Chain Bioaccumulation. Because of pyridine's low Kow (Verschueren 1983) and high water 
solubility (Sax and Lewis 1987), it probably will not bioconcentrate in plants, aquatic organisms, or 
animals. However, no data on bioconcentration factors or biomagnification in terrestrial or aquatic food 
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chains were located. Additional information on bioconcentration and biomagnification is needed to 
confirm the predicted limited importance of these processes in the environmental fate of pyridine. 
Exposure Levels in Environmental Media. Although pyridine has been identified in air, 
water, and sediments, data regarding pyridine concentrations in environmental media are sparse. The 
available data are insufficient to evaluate the potential for human exposure to this compound; 
therefore, human intake levels of pyridine from environmental media have not been estimated. 
Additional monitoring data for this compound in all media in the vicinity of identified potential 
pollution sources and at hazardous waste sites would be useful in assessing the potential for human 
exposure. In addition, identification and monitoring of those foods to which pyridine is added as a 
flavoring agent would increase the accuracy of estimates of human intake by this route of exposure. 
Exposure Levels in Humans. It would be useful to collect information on levels of exposure 
to pyridine in the environment that are associated with blood, urine, or tissue levels of pyridine and/or 
its metabolites in the exposed populations. Additional information relating those levels to the 
subsequent development of health effects would also be extremely useful. 
Exposure Registries. No exposure registries for pyridine were located. This compound is not 
currently one of the compounds for which a subregistry has been established in the National Exposure 
Registry. The compound will be considered in the future when chemical selection is made for 
subregistries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related 
to the exposure to this compound. 
5.7.2 On-going Studies 
Remedial investigations and feasibility studies conducted at the 4 NPL humans sites known to 
be contaminated with pyridine will add to the available database on exposure levels in environmental 
media, exposure levels in and exposure registries. 
No other on-going studies were located regarding the environmental transport, or potential for 






The purpose of this chapter is to describe the analytical methods that are available for detecting 
and/or measuring and monitoring pyridine in environmental media and in biological samples. The 
intent is not to provide an exhaustive list of analytical methods that could be used to detect and 
quantify pyridine. Rather, the intention is to identify well-established methods that are used as the 
standard methods of analysis. Many of the analytical methods used to detect pyridine in environmental 
samples are the methods approved by federal agencies such as EPA and the National Institute for 
Occupational Safety and Health (NIOSH). Other methods presented in this chapter are those that are 
approved by groups such as the Association of Official Analytical Chemists (AOAC) and the 
American Public Health Association (APHA). Additionally, analytical methods are included that refine 
previously used methods to obtain lower detection limits, and/or to improve accuracy and 
precision. 
As a volatile to semivolatile material, pyridine can be determined by gas chromatography (GC) 
analysis using mass spectrometric (MS) detection. Pyridine is usually collected from the gas phase on a 
column of solid sorbent, such as Tenax Pyridine can be removed from aqueous or slurry samples by 
purge-and-trap techniques or as headspace gas. Cryogenic (low temperature) collection and sorption in 
organic liquids are also possible. 
6.1 BIOLOGICAL MATERIALS 
In biological systems in which pyridine may have been metabolized or may itself be a 
metabolite, consideration should be given to the possible binding of the analyte by endogenous 
substances in the biological system. However, no information was found in the literature pertaining to 
such binding or to the release of biologically bound pyridine prior to analysis. 
Sensitive and selective methods are available for the qualitative and quantitative measurement 
of pyridine after it is separated from its sample matrix. Gas chromatography, using either sensitive and 
highly specific MS or highly sensitive flame ionization detection (FID), is the analytical method most 
commonly used. Capillary gas chromatography, also known as highresolution gas chromatography 
(HRGC), has facilitated the analysis of compounds such as pyridine that can be measured by gas 
chromatography and has resulted in improvements in resolution and sensitivity. It has made the choice 
of a stationary phase less important than was previously the case with packed columns. The 
instrumental capability to separate volatile analytes by HRGC is, for the most part, no longer the 
limiting factor in their analysis.  High-performance liquid chromatography (HPLC) has been used to 
measure isotopically labelled pyridine and its metabolites in urine (Shaker et al. 1982). This method 
has the advantage of compatibility with the liquid matrix of biological samples. 
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In biological samples, after pyridine is released from the sample matrix, it is usually determined 
by gas chromatography. Methods for the detection of pyridine in biological materials are summarized 
in Table 6-l. 
6.2 ENVIRONMENTAL SAMPLES 
For the determination of pyridine in air, the analyte is usually trapped and concentrated from a 
large volume of air on a solid sorbent, such as Tenax or activated carbon, from which it can be 
released thermally or eluted with a solvent such as dichloromethane for subsequent measurement. For 
aqueous samples, pyridine is purged with an inert gas, collected on a solid such as Tenax, or 
cryogenically collected, followed by thermal desorption and measurement. Gas chromatography using 
sensitive and highly specific MS or highly sensitive FID are the analytical methods of choice for the 
determination of pyridine in environmental samples. 
Methods for the determination of pyridine in environmental samples are summarized in Table 
6.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in 
consultation with the Administrator of EPA and agencies and programs of the Public Health Service) 
to assess whether adequate information on the health effects of pyridine is available. Where adequate 
information is not available, ATSDR, in conjunction with the NTP, is required to assure the initiation 
of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of pyridine. 
The following categories of possible data needs have been identified by a joint team of 
scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs 
that, if met, would reduce or eliminate the uncertainties of human health assessment. In the future, the 
identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be 
proposed. 
6.3.1 Data Needs 
Sensitive and selective methods are available for the qualitative and quantitative measurement 
of pyridine after it is separated from its sample matrix. 
An area of continuing interest is the ability to transfer analytes that have been isolated from a 
biological or environmental matrix quantitatively and in a narrow band to the HRGC; therefore this is 
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Another area of interest is to identify and accurately measure the quantity of compounds in the HRGC 
peaks. Mass spectrometric detection and Fourier transform infrared spectroscopy (FTIR) have been 
useful for this purpose. 
The metabolites of pyridine in biological materials are difficult to determine in routine practice 
because of the lack of standardized methods for their measurement. In addition, not all of the pyridine 
metabolites have been identified and characterized, and this must first be accomplished. 
Methods for Determining Biomarkers of Exposure and Effect. As with most xenobiotics, 
the identification of biomarkers of exposure to pyridine would be helpful in detecting exposure to this 
compound before adverse morphological or clinical effects occur. There is no available information in 
the literature that can be used to correlate levels of exposure to pyridine with resulting levels in urine 
or other biological fluids. Once biomarkers are identified, research on methods to detect them would 
be useful. 
Similarly, no methods have been identified that are sensitive enough to correlate levels in 
biological media with levels at which biological effects occur. The development of these methods 
would be useful in the protection of populations exposed to pyridine. 
Methods for Determining Parent Compounds and Degradation Products in 
Environmental Media. The media of most concern for human exposure to pyridine are drinking water 
(primarily from groundwater sources) and air. As illustrated by the data presented in Table 6-2 (e.g., 
Frei et al. 1974; NIOSH 1984; Sasai and Tsukioka 1981), the methods available for the determination 
of pyridine in water and air are not adequate to determine natural background levels of this compound. 
However, these background levels may well be insignificantly low. Methods are certainly adequate to 
measure the levels of pyridine at which known health effects occur. In general, the precision, accuracy, 
reliability, and specificity of methods to determine pyridine in water and air are not adequately 
documented. Additional work in this area would be useful. 
Methods for determining pyridine in water, air, and waste samples are undergoing constant 
improvement. For example, research is on-going to develop a "Master Analytical Scheme" for the 
determination of organic compounds, including pyridine, in water (Michael et al. 1988). The goal of 
this project is to detect and quantitatively measure organic compounds at 0.1 µg/L in drinking water, 1 
µg/L in surface waters, and 10 µg/L in effluent waters. Analytes are to include numerous nonvolatile 
compounds and some compounds that are only semisoluble in water, as well as volatile compounds (bp 
<150°C). 
Sampling methodologies for compounds such as pyridine continue to pose problems such as 
nonrepresentative samples, insufficient sample volumes, contamination, and the need for labor-intensive, 









6. ANALYTICAL METHODS 
simplified these procedures, it is desirable to have the means to measure organic compounds such as 
pyridine in situ in water and in other environmental media without the need for these sampling and 
extraction procedures to isolate the analyte prior to analysis. 
6.3.2 On-going Studies 
The Environmental Health Laboratory Sciences Division of the Center for Environmental 
Health and Injury Control, Centers for Disease Control, is developing methods for the analysis of 
pyridine and other volatile organic compounds in blood. These methods use high resolution gas 
chromatography and magnetic sector mass spectrometry which gives detection limits in the low 
parts per trillion range. 
The Cooperative Institute for Research in Environmental Sciences (CIRES) at the University of 
Colorado, Boulder, is conducting research to improve methods of analysis for pyridine and related 
compounds in environmental samples. 
Improvements continue to be made in chromatographic separation and detection. Problems 
associated with the collection of pyridine on a sorbent trap, followed by thermal sorption, may be 
overcome with direct purging to a capillary column with whole column cryotrapping (Pankow and 
Rosen 1988) or by trapping on a very thick film (about 100 pm) of cross-linked silicone 
(Roeraade and Blomberg 1989). Current activities in the areas of supercritical fluid extraction (King 
1989) and supercritical fluid chromatography (Smith 1988) include determination of compounds such 
as pyridine in biological samples and environmental media. Fourier transform infrared flow cell 
detectors are sensitive and selective for the detection of compounds such as pyridine that have been 
separated by supercritical fluid chromatography (Wieboldt et al. 1988). Immunoassay methods of 
analysis are also promising for the determination of various organic substances, and it is 






7. REGULATIONS AND ADVISORIES 
Because of its potential to cause adverse health effects in exposed people, a number of 
regulations and guidelines have been established for pyridine by various national and state agencies. 
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Acute Exposure -- Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption Coefficient (Koc) -- The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment or soil (i.e., the solid 
phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid 
phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per 
gram of soil or sediment. 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a chemical in aquatic 
organisms at a specific time or during a discrete time period of exposure divided by the concentration 
in the surrounding water at the same time or during the same period. 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study, or group of studies, that 
produces significant increases in the incidence of cancer (or tumors) between the exposed population 
and its appropriate control. 
Carcinogen -- A chemical capable of inducing cancer. 
Ceiling Value -- A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure -- Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Developmental Toxicity -- The occurrence of adverse effects on the developing organism that may 
result from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any 
point in the life span of the organism. 
Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as a result of prenatal exposure 
to a chemical; the distinguishing feature between the two terms is the stage of development during 
which the insult occurred. The terms, as used here, include malformations and variations, altered 
growth, and in utero death. 
EPA Health Advisory -- An estimate of acceptable drinking water levels for a chemical substance 






but serves as technical guidance to assist federal, state, and local officials. 
Immediately Dangerous to Life or Health (IDLH) -- The maximum environmental concentration of 
a contaminant from which one could escape within 30 min without any escape-impairing symptoms or 
irreversible health effects. 
Intermediate Exposure -- Exposure to a chemical for a duration of 15-364 days as specified in the 
Toxicological Profiles. 
Immunologic Toxicity -- The occurrence of adverse effects on the immune system that may result 
from exposure to environmental agents such as chemicals. 
In Vitro -- Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo -- Occurring within the living organism. 
Lethal Concentration(LO) (LC50) -- The lowest concentration of a chemical in air which has been 
reported to have caused death in humans or animals. 
Lethal Concentration (50) (LC50) -- A calculated concentration of a chemical in air to which exposure 
for a specific length of time is expected to cause death in 50% of a defined experimental animal 
population. 
Lethal Dose(LO) (LD50) -- The lowest dose of a chemical introduced by a route other than inhalation 
that is expected to have caused death in humans or animals. 
Lethal Dose(50) (LD50) -- The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50) -- A calculated period of time within which a specific concentration of a 
chemical is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of chemical in a study or 
group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Malformations -- Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level -- An estimate of daily human exposure to a chemical that is likely to be without 

















Mutagen -- A substance that causes mutations. A mutation is a change in the genetic material in a 
body cell. Mutations can lead to birth defects, miscarriages, or cancer. 
Neurotoxicity -- The occurrence of adverse effects on the nervous system following exposure to 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL) -- The dose of chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen 
between the exposed population and its appropriate control. Effects may be produced at this dose, but 
they are not considered to be adverse. 
Octanol-Water Partition Coefficient (Kow) -- The equilibrium ratio of the concentrations of a 
chemical in n-octanol and water, in dilute solution. 
Permissible Exposure Limit (PEL) -- An allowable exposure level in workplace air averaged over an 
8-hour shift. 
q1* -- The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps an order of magnitude) of 
the daily exposure of the human population to a potential hazard that is likely to be without risk of 
deleterious effects during a lifetime. The RfD is operationally derived from the NOAEL (from
animal and human studies) by a consistent application of uncertainty factors that reflect various types 
of data used to estimate RfDs and an additional modifying factor, which is based on a professional 
judgment of the entire database on the chemical. The RfDs are not applicable to nonthreshold effects 
such as cancer. 
Reportable Quantity (RQ) -- The quantity of a hazardous substance that is considered reportable 
under CERCLA. Reportable quantities are: (1) 1 lb or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities 
are measured over a 24-hour period. 
Reproductive Toxicity -- The occurrence of adverse effects on the reproductive system that may 
result from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the 
related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual 
behavior, fertility, pregnancy outcomes, or modifications in other functions that are Dependent on the 





Short-Term Exposure Limit (STEL) -- The maximum concentration to which workers can be 
exposed for up to 15 min continually. No more than four excursions are allowed per day, and there 
must be at least 60 min between exposure periods. The daily TLV-TWA may not be exceeded. 
Target Organ Toxicity -- This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single 
limited exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen -- A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV) -- A concentration of a substance to which most workers can be 
exposed without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL. 
Time-weighted Average (TWA) -- An allowable exposure concentration averaged over a normal 8-
hour workday or 40-hour workweek. 
Toxic Dose (TD50) -- A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Uncertainty Factor (UF) -- A factor used in operationally deriving the RfD from experimental data. 
UFs are intended to account for (1) the variation in sensitivity among the members of the human 
population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in 
extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the 

























Public Health Statement 
This chapter of the profile is a health effects summary written in nontechnical language. Its intended 
audience is the general public especially people living in the vicinity of a hazardous waste site or 
substance release. If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the substance. 
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence 
that will direct the reader to chapters in the profile that will provide more information on the given 
topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize health effects by duration of 
exposure and endpoint and to illustrate graphically levels of exposure associated with those effects. All 
entries in these tables and figures represent studies that provide reliable, quantitative estimates of No­
Observed-Adverse-Effect Levels (NOAELS), Lowest-Observed- Adverse-Effect Levels (LOAELs) for 
Less Serious and Serious health effects, or Cancer Effect Levels (CELs). In addition, these tables and 
figures illustrate differences in response by species, Minimal Risk Levels (MRLs) to humans for 
noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime 
cancer risk of 1 in 10,000 to 1 in 10,000,000. The LSE tables and figures can be used for a quick 
review of the health effects and to locate data for a specific exposure scenario. The LSE tables and 
figures should always be used in conjunction with the text. 
The legends presented below demonstrate the application of these tables and figures. A representative 
example of LSE Table 2-l and Figure 2-l are shown. The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 2-l 
(1). Route of Exposure One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. When 
















three LSE tables and two LSE figures are presented in the document. The three LSE tables 
present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE 
Table 2-1, 2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE Figure 2­
l) and oral (LSE Figure 2-2) routes. 
(2.) Exposure Duration Three exposure periods: acute (14 days or less); intermediate (15 to 364 
days); and chronic (365 days or more) are presented within each route of exposure. In this 
example, an inhalation study of intermediate duration exposure is reported. 
(3.) Health Effect The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the “System” column of the LSE table.  
(4.) Key to Figure Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to define a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in Figure 2-l). 
(5.) Species The test species, whether animal or human, are identified in this column. 
(6.) Exposure Frequency/Duration The duration of the study and the weekly and daily exposure 
regimen are provided in this column. This permits comparison of NOAELs and LOAELs from
different studies. In this case (key number 18), rats were exposed to [substance x] via inhalation 
for 13 weeks, 5 days per week, for 6 hours per day. 
(7.) System This column further defines the systemic effects. These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not 
covered in these systems. In the example of key number 18, one systemic effect (respiratory) 
was investigated in this study. 
(8.) NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at 
which no harmful effects were seen in the organ system studied. Key number 18 reports a 
NOAEL of 3 ppm for the respiratory system which was used to derive an intermediate 
exposure, inhalation MRL of 0.005 ppm (see footnote “c”). 
(9.) LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest exposure level used 
in the study that caused a harmful health effect. LOAELs have been classified into "Less 
Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at 
which adverse health effects first appear and the gradation of effects with increasing dose. A 




quantify the adverse effect accompanies the LOAEL. The "Less Serious" respiratory effect 
reported in key number 18 (hyperplasia) occurred at a LOAEL of 10 ppm. 
(10). 	 Reference The complete reference citation is given in Chapter 8 of the profile. 
(11). 	 CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiological studies. CELs are always considered serious 
effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses which did not cause a measurable increase in cancer. 
(12). 	 Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "c" indicates the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See LSE Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the 
reader quickly compare health effects according to exposure levels for particular exposure duration. 
(13). 	 Exposure Duration The same exposure periods appear as in the LSE table. In this example, 
health effects observed within the intermediate and chronic exposure periods are illustrated. 
(14).	 Health Effect These are the categories of health effects for which reliable quantitative data 
exist. The same health effects appear in the LSE table. 
(15).	 Levels Of Exposure Exposure levels for each health effect in the LSE tables are graphically 
displayed in the LSE figures. Exposure levels are reported on the log scale "y" axis. Inhalation 
exposure is reported in mg/m3 or ppm and oral exposure is reported in mg/kg/day. 
(16).	 NOAEL In this example, 18r NOAEL is the critical end point for which an intermediate 
inhalation exposure MRL is based. As you can see from the LSE figure key, the open-circle 
symbol indicates a NOAEL for the test species (rat). The key number 18 corresponds to the 
entry in the LSE table. The dashed descending arrow indicates the extrapolation from the 
exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" 
in the LSE table). 
(17).	 CEL Key number 38r is one of three studies for which Cancer Effect Levels (CELs) were 
derived. The diamond symbol refers to a CEL for the test species (rat). The number 38 







(18). Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the 
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer 
dose response curve at low dose levels (q1*). 









Chapter 2 (Section 2.4) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based on evaluations of 
existing toxicological, epidemiological, and toxicokinetic information. This summary is designed to 
present interpretive, weight-of-evidence discussions for human health end points by addressing the 
following questions. 
1.What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans? 
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The section discusses health effects by end point. Human data are presented first, then animal data. 
Both are organized by route of exposure (inhalation, oral, and dermal) and by duration (acute, 
intermediate, and chronic). In vitro data and data from parenteral routes (intramuscular, intravenous, 
subcutaneous, etc.) are also considered in this section. If data are located in the scientific literature, a 
table of genotoxicity information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, andcardinogenic data. ATSDR does not currently assess cancer 
potency or perform cancer risk assessments. MRLs for noncancer end points if derived, and the end 
points from which they were derived are indicated and discussed in the appropriate section(s). 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to 
public health are identified in the Identification of Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information was available, MRLs were derived. MRLs are specific for 
route (inhalation or oral) and duration (acute, intermediate, or chronic) of exposure. Ideally, MRLs can 
be derived from all six exposure scenarios (e.g., Inhalation - acute, -intermediate, -chronic; Oral -
acute, - intermediate, - chronic). These MRLs are not meant to support regulatory action, but to aquaint 
health professionals with exposure levels at which adverse health effects are not expected to occur in 
humans. They should help physicians and public health officials determine the safety of a community 
living near a substance emission, given the concentration of a contaminant in air or the estimated daily 
dose received via food or water. MRLs are based largely on toxicological studies in animals and on 










MRL users should be familiar with the toxicological information on which the number is based. 
Section 2.4, "Relevance to Public Health," contains basic information known about the substance. 
Other sections such as 2.6, "Interactions with Other Chemicals" and 2.7, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version of the risk assessment methodology used by the Environmental Protection Agency 
(EPA) (Barnes and Dourson, 1988; EPA 1989a) to derive reference doses (RfDs) for lifetime exposure. 
To derive an MRL, ATSDR generally selects the end point which, in its best judgement, represents the 
most sensitive humanhealth effect for a given exposure route and duration. ATSDR cannot make this 
judgement or derive an MRL unless information (quantitative or qualitative) is available for all 
potential effects (e.g., systemic, neurological, and developmental). In order to compare NOAELs 
and LOAELs for specific end points, all inhalation exposure levels are adjusted for 24hr exposures and 
all intermittent exposures for inhalation and oral routes of intermediate and chronic duration are 
adjusted for continous exposure (i.e., 7 days/week). If the information and reliable quantitative data on 
the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when 
information from multiple species is available) with the highest NOAEL that does not exceed any 
adverse effect levels. The NOAEL is the most suitable end point for deriving an MRL. When a 
NOAEL is not available, a Less Serious LOAEL can be used to derive an MRL, and an uncertainty 
factor (UF) of 10 is employed. MRLs are not derived from Serious LOAELs. Additional uncertainty 
factors of 10 each are used for human variability to protect sensitive subpopulations (people 
who are most susceptible to the health effects caused by the substance) and for interspecies variability 
(extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are 
multiplied together. The product is then divided into the adjusted inhalation concentration or oral 
dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are 













A peer review panel was assembled for pyridine. The panel consisted of the following 
members: Dr. Edmond LaVoie, Professor, Medicinal Chemistry, Rutgers University; Dr. James 
Withey, Research Scientist, Health and Welfare, Canada; Dr. Joseph Sincheiner, Professor, 
Toxicology, University of Michigan. These experts collectively have knowledge of pyridine's physical 
and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and 
animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with 
the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environment 
Response, Compensation, and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have 
reviewed the peer reviewers' comments and determined which comments will be included in the 
profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief 
explanation of the rationale for their exclusion, exists as part of the administrative record for 
this compound. A list of databases reviewed and a list of unpublished documents cited are also 
included in the administrative record.  
The citation of the peer review panel should not be understood to imply its approval of the 
profile's final content. The responsibility for the content of this profile lies with the ATSDR. 
